secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2026-08-12T11:03:08+00:00
Accession:  0001104659-26-094440
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q2: Symvess sales up, net loss $36.8M; V012 Phase 3 hits primary endpoint
--------------------------------------------------------------------------------

- Q2 2026 Symvess sales $0.4M vs $0.1M prior year; net loss $36.8M vs $37.7M.
- V012 Phase 3 interim: ATEV beat AV fistula, 91 more catheter-free days (p=0.0007), infections 6 vs 23/100 pt-yrs.
- Plans sBLA for dialysis access with FDA in H2 2026; FDA accepted IND for CTEV in CABG, Phase 2a expected Q3 2026.
- Raised $57.5M gross in June public offering; restructuring cuts ~45 staff, saving ~$14.3M in 2026.
- Cash $80.3M at 6/30/26; six-month net loss $54.4M vs net income $1.5M year ago.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/0001104659-26-094440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/tm2622949d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer